Wedbush Maintains Outperform Rating on Kiniksa Pharmaceuticals, Keeps $102 Target
Wedbush maintained its Outperform rating on Kiniksa Pharmaceuticals and set a $102 price target. The target implies 14.3% upside from the Oct. 27 close of $89.20.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.